Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 +/- 22.6% in macro- and 72.8 +/- 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido [1,3,28,29,30].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [30]
In the citing paper
“Further research has reported the recovery of other hormonal axes following adenoma shrinkage (227)”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [227]
Citations
Cites
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Self-citationSex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationColao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Self-citationNew approach to the diagnosis of growth hormone deficiency in adults
Ghigo, E., Aimaretti, G., Gianotti, L., Bellone, J., Arvat, E., & Camanni, F. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340352 · Cited by 257
Di Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Self-citationColao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
Self-citationTreatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
Biller, B. M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2338 · Cited by 216
Cited by
Items 101–200 of 260
Mild hyperprolactinemia in a couple: What impact on fertility?
Maiter, D. M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.04.002 · Cited by 21
Aldahmani, K. M., Almalki, M., Ekhzaimy, A. A., Aziz, F., Bashier, A. M., Mahzari, M. M., & Beshyah, S. (2022) · Pituitary · doi:10.1007/s11102-022-01242-y · Cited by 21
Yedinak, C. G., Cetas, I., Ozpinar, A., McCartney, S., Dog⫧an, A., & Fleseriu, M. (2016) · Endocrine · doi:10.1007/s12020-016-1042-2 · Cited by 20
Machen, G. L., & Sandlow, J. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-32300-4_1 · Cited by 20
Disorders of Prolactin Secretion and Prolactinomas
Bronstein, M. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00007-x · Cited by 20
Pouratian, N., Asthagiri, A. R., Schiff, D., & Sheehan, J. P. (2010) · Blue books of neurology · doi:10.1016/b978-0-7506-7516-1.00011-6 · Cited by 20
Walia, R., Bhansali, A. K., Dutta, P. R., Khandelwal, N., Sialy, R., & Bhadada, S. K. (2011) · PubMed Central · Cited by 20
Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Bhansali, A. K., Walia, R., Dutta, P. R., Khandelwal, N., Sialy, R., & Bhadada, S. K. (2010) · PubMed · Cited by 19
Non-surgical management of hormone-secreting pituitary tumors
Patil, C. G., Gephart, M. H., Katznelson, L. J., & Chang, S. D. (2009) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2008.11.001 · Cited by 19
Raut, S., Kumar, A. V., Khambata, K., Deshpande, S., & Balasinor, N. (2020) · Biochemical Journal · doi:10.1042/bcj20190946 · Cited by 18
Sexual Dysfunction in Men and Women
Bhasin, S., & Basson, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00020-4 · Cited by 19
Testosterone replacement therapy: role of pituitary and thyroid in diagnosis and treatment
Crawford, M., & Kennedy, L. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.01 · Cited by 17
The Role of Aromatase Inhibitors in Male Prolactinoma
Akirov, A., & Rudman, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041437 · Cited by 16
Ceccato, F., Lizzul, L., Voltan, G., Barbot, M., & Scaroni, C. M. (2021) · Pituitary · doi:10.1007/s11102-021-01165-0 · Cited by 15
Rudman, Y., Duskin‐Bitan, H., Manisterski, Y., Pertzov, B., Akirov, A., Masri‐Iraqi, H., & Shimon, I. (2021) · Clinical Endocrinology · doi:10.1111/cen.14541 · Cited by 15
Prolactin in Human Reproduction
Molitch, M. E. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00003-2 · Cited by 15
Yan, Z., & Lei, T. (2022) · Brain Sciences · doi:10.3390/brainsci12060796 · Cited by 15
Semen quality in patients with pituitary disease and adult-onset hypogonadotropic hypogonadism
Andreassen, M., Juul, A., Feldt‐Rasmussen, U., & Jørgensen, N. (2018) · Endocrine Connections · doi:10.1530/ec-18-0061 · Cited by 14
Giant prolactinomas in adolescence: an uncommon cause of blindness
Semple, P., Fieggen, G. A. G., Parkes, J., & Levitt, N. S. (2006) · Child s Nervous System · doi:10.1007/s00381-006-0177-5 · Cited by 14
Testosterone and Glucose Homeostasis in Adult Males: Current Insights and Future Prospects
Milionis, C., Koukkou, E. G., Venaki, E., & Ilias, Ι. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436184.81 · Cited by 12
van der Meulen, M., Najafabadi, A. H. Z., Lobatto, D. J., van den Hout, W. B., Andela, C. D., Zandbergen, I. M., Pereira, A. M., van Furth, W. R., Vlieland, T. P. M. V., & Biermasz, N. R. (2020) · Pituitary · doi:10.1007/s11102-020-01089-1 · Cited by 12
Kurosaki, M., Kambe, A., Ishibashi, M., Watanabe, T., & Horie, Y. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0175-3 · Cited by 12
Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas
Kurosaki, M., Kambe, A., Watanabe, T., Fujii, S., & Ogawa, T. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000457 · Cited by 12
Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma
Ruano, M., Boronat, M., Pino, A. O., Perez, C. R., Nuñez, M. G., Arencibia, D. M., & Mogollón, F. J. N. (2010) · Pituitary · doi:10.1007/s11102-010-0237-4 · Cited by 12
Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets
Hjelholt, A. J., Tei, R., Diener, H. C., & Jørgensen, J. O. L. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70098 · Cited by 11
Raut, S., Khambata, K., Goffin, V., & Balasinor, N. (2023) · Endocrinology · doi:10.1210/endocr/bqad072 · Cited by 11
Sudha, N., & Enoch, I. V. M. V. (2015) · Journal of Solution Chemistry · doi:10.1007/s10953-015-0355-8 · Cited by 11
Giant prolactinomas: Multi-modal approach to achieve tumor control
Shimon, I. (2017) · Endocrine · doi:10.1007/s12020-016-1225-x · Cited by 11
Is There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)?
Çayan, S., Altay, B., Rambhatla, A., Colpi, G. M., & Agarwal, A. K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010185 · Cited by 11
Long-Term Management of Prolactinomas—Use of Long-Acting Dopamine Agonists
Cook, D. M. (2005) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-005-5220-4 · Cited by 10
The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma
Gürbüz, F., Yağcı‐Küpeli, B., Kör, Y., Yüksel, B., Zorludemir, S., Gürbüz, B. B., & Küpeli, S. (2013) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0151 · Cited by 10
Hypopituitarism patterns among adult males with prolactinomas
Peng, J., Qiu, M., Qi, S., Li, D., & Peng, Y.-P. (2016) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2016.01.029 · Cited by 10
Visual morbidity in macroprolactinoma: A retrospective cohort study
Rudman, Y., Duskin‐Bitan, H., Masri‐Iraqi, H., Akirov, A., & Shimon, I. (2024) · Clinical Endocrinology · doi:10.1111/cen.15120 · Cited by 9
Gillam, M. P., & Molitch, M. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10015-x · Cited by 13
Behan, L., Moyles, P., Cuesta, M., Rogers, B., Crowley, R. K., Ryan, J., Brennan, P., Smith, D., Tormey, W. P., Sherlock, M., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13355 · Cited by 9
The Use of High-Dose Daily Cabergoline in an Adolescent Patient With Macroprolactinoma
Howell, D. L., Wasilewski, K., Mazewski, C., Hudgins, R. J., & Meacham, L. R. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000168727.41896.d2 · Cited by 9
Rudman, Y., Simon, N., Shimon, R., Drozdinsky, G., Markus, E., Duskin‐Bitan, H., Masri‐Iraqi, H., Tsvetov, G., Akirov, A., & Shimon, I. (2025) · Endocrine · doi:10.1007/s12020-025-04215-w · Cited by 8
Clinical management of difficult to treat macroprolactinomas
Sahakian, N., Castinetti, F., Dufour, H., Graillon, T., Romanet, P., Barlier, A., Brue, T. C., & Cuny, T. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1596024 · Cited by 8
Endocrine evaluation of pituitary tumours
Saunders, S. L., & Vora, J. P. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690802385974 · Cited by 8
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
Cuevas, J. L., Fernández, V., Rojas, D., Nelson Wohllk, G., González, Ó., & Torche, E. (2013) · Revista médica de Chile · doi:10.4067/s0034-98872013000600001 · Cited by 8
Iglesias, P., & Díez, J. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.12.023 · Cited by 7
Indications for surgical treatment of prolactin-secreting pituitary adenomas
Kalinin, P. L., Астафьева, Л. И., Кадашев, Б. А., & Ismailov, D. B. (2017) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro2017815117-124 · Cited by 7
Zúñiga, D., Stumpf, M. A. M., Monteiro, A. L. S., & Glezer, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02231-z · Cited by 7
Hajder, M., Hajder, E., Dervisefendic, M., Samardzic, R., & Alic, E. (2013) · Medical Archives · doi:10.5455/medarh.2013.67.181-184 · Cited by 7
Allan, C. A., & McLachlan, R. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00139-6 · Cited by 7
Kukk, A. J. (2011) · The Atrium (University of Guelph) · Cited by 7
Rudman, Y., & Shimon, I. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.11.001 · Cited by 6
True hyperprolactinemia in men without visible pituitary adenoma
Shimon, I., Rudman, Y., Manisterski, Y., Gorshtein, A., Masri‐Iraqi, H., & Duskin‐Bitan, H. (2021) · Endocrine · doi:10.1007/s12020-021-02624-1 · Cited by 6
Gamma knife radiosurgery for high-risk lactotroph adenomas: Long-term results
Kara, M., Samancı, Y., Yılmaz, M., Şengöz, M., & Peker, S. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.01.025 · Cited by 6
Treatment of hyperprolactinemia
Moustafa, H. F., Rizk, B. M., Helvacioglu, A., & Gilmore, S. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762390.021 · Cited by 6
Detomas, M., Altieri, B., Nasi‐Kordhishti, I., Ryba, A. S., Haberbosch, L., Chierigo, F., Deutschbein, T., Faßnacht, M., Mortini, P., Flitsch, J., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02559-8 · Cited by 5
Approach to the Patient With Dopamine-Resistant Microprolactinoma
Glezer, A., Stumpf, M. A. M., & Queiroz, N. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf624 · Cited by 5
Chanson, P., & Maiter, D. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00011-1 · Cited by 5
Diagnosing and treating the elderly individual with hypopituitarism
Corsello, A., Paragliola, R. M., & Salvatori, R. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09870-w · Cited by 5
Maiter, D. M. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11836-5_11 · Cited by 5
Allan, C. A., & McLachlan, R. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00139-8 · Cited by 5
Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery
Prinzi, A., Fava, G., Bacchi, I., Federica, S., Galvano, A., Arnaldi, G., Frasca, F., Guarnotta, V., & Malandrino, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1705300 · Cited by 4
Fertility and pregnancy in patients with prolactinoma
Stumpf, M. A. M., Queiroz, N. L., & Glezer, A. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102081 · Cited by 4
Heneghan, L. J., Tsang, A., Dimino, C., Khandji, A. G., Panigrahi, S. K., & Page‐Wilson, G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad545 · Cited by 4
Acquired Disorders of the Hypothalamo‐Pituitary Axis
Alatzoglou, K. S., & Dattani, M. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch5 · Cited by 4
Endocrine-Related Sexual Dysfunction in Young People
Talaulikar, V. S., & Sangster, P. (2024) · Endocrinology · doi:10.1007/978-3-030-18901-3_15-1 · Cited by 4
Prolactinomas: Diagnosis and~Management
Shibli-Rahhal, A. A., & Schlechte, J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-264-9_6 · Cited by 4
CSF Rhinorrhea: An Early Complication of Dopamine-Sensitive Macroprolactinoma
Padmanabhuni, A., Hopkins, R. L., Chin, L. S., & Dhaliwal, R. (2016) · AACE Clinical Case Reports · doi:10.4158/ep161457.cr · Cited by 4
Treatment of hyperprolactinemia: A single-institute experience
Chen, T., Lee, C.-H., Yang, M., Shen, C., Yang, Y.-P., Chien, Y., Huang, Y.-F., Lai, C.-M., & Cheng, W.-Y. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000584 · Cited by 4
Razzaq, A. A., Jooma, R., & Ahmed, S. (2006) · PubMed · Cited by 4
Other Endocrinopathies and the Nervous System
Jay, C. A., & Abrams, G. (2008) · Elsevier eBooks · doi:10.1016/b978-044306707-5.50026-2 · Cited by 4
Raut, S., Khambata, K., Singh, D., & Balasinor, N. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02471-7 · Cited by 3
Prolactinoma e hiperprolactinemia. Posicionamiento de la SMNE
Rivera-Hernández, A. D. J., Domínguez, B., Ramírez‐Rentería, C., Ramos, D. C., Sosa-Eroza, E., Espinosa-Cárdenas, E., Rangel, G., Hinojosa-Amaya, J. M., Vidrio-Velázquez, M., Mercado-Atri, M., et al. (2023) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000026 · Cited by 3
Çaklılı, Ö. T., Ok, A. M., İstemihan, Z., Selçukbiricik, Ö. S., & Yarman, S. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.11.005 · Cited by 3
Hyperprolactinemia syndrome in women: diagnosis and correction
Захаров, И. С., Shmidt, А. А., Timoshkova, Y. L., & Silaeva, E. A. (2022) · Russian Military Medical Academy Reports · doi:10.17816/rmmar101271 · Cited by 3
Therapie der Hypophysenüberfunktion
Schäffler, A. (2006) · Der Internist · doi:10.1007/s00108-006-1727-3 · Cited by 3
Calibration Procedure for 3D Surface Measurements using Stereo Vision and Laser Stripe
Vilaça, J. L., Fonseca, J. C., & Pinho, A. (2006) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 3
Cabergoline Effectively Induced Remission of Prolactinoma in a 9-year-old Japanese Boy
Sano, H. I., Takigami, M., Ogino, T., Morioka, K., Ito, T., Sudo, A., & Fukushima, N. (2009) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.18.65 · Cited by 3
Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
Menon, L., & Rahman, W. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211029750 · Cited by 3
Elleuch, M., Frikha, H., Loukil, F., Boujelben, K., Salah, D. B., & Rekik, N. M. (2025) · Biomedicines · doi:10.3390/biomedicines13051125 · Cited by 2
Hypopituitarism in patients with prolactinomas: a narrative review
Campana, C., Patelli, I., Arecco, A., Ferone, D., Boschetti, M., & Gatto, F. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102082 · Cited by 2
Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas
Rudman, Y., & Shimon, I. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102095 · Cited by 2
Полежаев, А. В., Cherebillo, V. Y., Свистов, Д. В., Tsoy, U. A., & Войцеховский, Д. В. (2018) · Grekov s Bulletin of Surgery · doi:10.24884/0042-4625-2018-177-3-14-18 · Cited by 2
Pituitary adenomas: current principles of diagnosis and treatment
Astafyeva, L. I., Chernov, I. V., Chekhonin, I. V., Shults, E. I., Pronin, I., & Kalinin, P. L. (2021) · Russian journal of neurosurgery · doi:10.17650/1683-3295-2020-22-4-94-111 · Cited by 2
Demba, D., Mané, D. I., Maguette, M., Sow, D., Ndiaye, F. M., Assane, N. M., Mouhamed, D., Gadji, F. K., Thioye, E. M. M., Charles, H., et al. (2023) · Open Journal of Internal Medicine · doi:10.4236/ojim.2023.133017 · Cited by 2
Diagnosis and treatment of prolactinoma: clinical analysis of 124 prolactinomas
Han, L., Shu, K., & You, C. (2008) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-007-0145-x · Cited by 2
Diagnosis and treatment of prolactinomas
Ježková, J., & Marek, J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.2.135 · Cited by 2
Principles and Pitfalls of Anesthesia for Transsphenoidal Surgery
Dunn, L. K., & Nemergut, E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-56691-7_3 · Cited by 2
Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox
Tamagno, G., Daly, A., Deprez, M., Vroonen, L., Andris, C., Martin, D., & Beckers, A. M. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.07.003 · Cited by 2
Evaluation of therapy with cabergoline in men with macroprolactinoma
Andrysiak-Mamos, E., Kaźmierczyk-Puchalska, A., Żochowska, E., Sowińska-Przepiera, E., Sagan, L. M., Kojder, I., & Syrenicz, A. (2016) · Pomeranian Journal of Life Sciences · doi:10.21164/pomjlifesci.95 · Cited by 2
Endocrinology of male sexual dysfunction
Janmohamed, S. G., & Bouloux, P.-M. G. (2016) · Wiley eBooks · doi:10.1002/9781118746509.ch5 · Cited by 2
Giant prolactinoma, a case report and review of the literature
Homyani, D. K. A., Khalifah, R. A. A., Tuwaijri, I. S. A., Al-Jurayyan, R. N. A., & Jurayyan, N. A. M. A. (2019) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2019.100048 · Cited by 2
Macroprolactinoma in a young man presenting with erectile dysfunction
Song, S., Lee, J., & Kim, D. S. (2019) · Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine · doi:10.5653/cerm.2019.00339 · Cited by 2
Ohouana, R. M., Gbimbouza, S. I. T., Mbaki, H. B. E., Mbamognoua, N. G. A., Elenga-Bongo, C., Okoumou-Moko, A., Ongoth, F. E. M., Bouénizabila, E., & Monabeka, H. G. (2021) · HEALTH SCIENCES AND DISEASE · doi:10.5281/hsd.v22i9.2954 · Cited by 2
Gibson, M., & Hammoud, A. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-52210-4_11 · Cited by 2
Diagnosis and new treatment options for pituitary adenomas
Grigoriev, A. Y., Неронович, А. В., Иващенко, О. В., & Starkov, G. Y. (2023) · Problems of Endocrinology · doi:10.14341/probl13199 · Cited by 2
Aspects of diagnosis and treatment of hypopituitarism in adult life
Nyström, H. F. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 2
Bağır, G. Ş., Güneşli, A., Haydardedeoğlu, F. E., Bakıner, O., Alkan, Ö., & Ertörer, M. E. (2020) · Endocrinology research and practice. · doi:10.25179/tjem.2020-77688 · Cited by 1
Prolactinoma-associated headache: Clinical and radiological correlates and long-term outcomes
Andereggen, L., Schankin, C. J., Schüetz, P., Stieger, A., Luedi, M. M., Cihan, A., Roethlisberger, M., Mariani, L., Beck, J., & Christ, E. (2026) · Pituitary · doi:10.1007/s11102-026-01699-1 · Cited by 1
Hjelholt, A. J., Laugesen, K., Tei, R., Kasch, H., Diener, H., & Jørgensen, J. O. L. (2026) · Cephalalgia Reports · doi:10.1177/25158163261464939 · Cited by 1
Prolactinoma: Diagnosis, Treatment, and Follow-up (A Review Article)
Kashi, Z., & Bahar, A. (2012) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Māzandarān/Journal of Mazandaran University of Medical Sciences · Cited by 1
Hormonal Evaluation and Therapy in Erectile Dysfunction
Moreno, S. A., & Morgentaler, A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-536-1_12 · Cited by 1
Dawson, A. J., Rowland-Hill, C., & Atkin, S. L. (2010) · BMJ · doi:10.1136/bmj.c2966 · Cited by 1
Principles and Pitfalls of Anesthesia for Transsphenoidal Surgery
Nemergut, E. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-0292-5.00003-6 · Cited by 1
Moustafa, H. F., Helvacioglu, A., Rizk, B. M., Nawar, M. G., Rizk, C. B., Rizk, C. B., Ragheb, C., Rizk, D. B., & Sherman, C. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547287.032 · Cited by 1
Metadata
- Authors
- Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Colao, Annamaria
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1704-1711
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2091047975
- Semantic Scholar
- 1e7fe5139d0e093e73f435b5c99704ece8f0a0ef
- Cited by
- 256
- References
- 28
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- cabergoline, prolactinoma, macroprolactinoma, microprolactinoma, prolactin normalization, tumor shrinkage, pituitary function recovery, hypogonadism, testosterone, semen quality, sperm count, sperm motility, visual field defects, headache, galactorrhea, hypopituitarism, dopamine agonists
- MeSH terms
- Cabergoline, Adolescent, Adult, Aged, Drug Administration Schedule, Ergolines, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland, Pituitary Neoplasms, Prolactin, Semen, Prolactinoma, Treatment Outcome, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.